Advanced search
Publication Cover
Leukemia & Lymphoma Volume 48, 2007 - Issue 5
Submit an article Journal homepage
89
Views
4
CrossRef citations to date
0
Altmetric
Original

High dose CHOP: A phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351

Bruce A. Peterson University of Minnesota, Minneapolis, MN, USACorrespondence[email protected]
, MD,
Jeffrey Johnson The CALGB Statistical Center, Durham, NC, USA
,
Margaret A. Shipp Dana-Farber Cancer Institute, Boston, MA, USA
,
Maurice Barcos Roswell Park Cancer Institute, Buffalo, NY, USA
,
Jon P. Gockerman Duke University Medical Center, Durham, NC, USA
,
George P. Canellos Dana-Farber Cancer Institute, Boston, MA, USA
&
For the Cancer and Leukemia Group B University of Minnesota, Minneapolis, MN, USA
 show all
Pages 870-880 | Received 22 Jun 2006, Accepted 03 Feb 2007, Published online: 01 Jul 2009

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Jonathan Reiss, Brian Link, Jia Ruan, Richard Furman, Morton Coleman, John Leonard & Peter Martin. (2015) Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma. Leukemia & Lymphoma 56:10, pages 2870-2875.
Read now
Fernando Cabanillas. (2007) Dose dense CHOP: When more is not always better!. Leukemia & Lymphoma 48:5, pages 845-846.
Read now

Articles from other publishers (2)

Marijke Linschoten, Janine A M Kamphuis, Anna van Rhenen, Laurens P Bosman, Maarten J Cramer, Pieter A Doevendans, Arco J Teske & Folkert W Asselbergs. (2020) Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis. The Lancet Haematology 7:4, pages e295-e308.
Crossref
. (2008) Current Awareness in Hematological Oncology. Hematological Oncology 26:1, pages 46-53.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.